RadarScreener › GCTK

GCTK

Glucotrack, Inc.
Nasdaq · Surgical & Medical Instruments & Apparatus · EDGAR filings (CIK 1506983) · 21 signals · 3 setups · updated Aug 16, 2026

What the filings say Pressure ▼

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.

Radar 91 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 0.9 mo · strongest signal: Equity line (Aug 5, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

91Radar · attention score (0–100)
91Dilution pressure · financing + balance sheet
67Listing risk · exchange standards
33Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.95

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language, negative equity, runway < 6 months) coexists with live selling machinery (atm program, convertible note, equity line, pipe). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
ATM programConvertible noteEquity lineGoing-concern languageNegative equityPIPERunway < 6 months

Listing cliff Pressure ▼ strength 0.80

Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.

Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Going-concern languageMinimum bid deficiencyNear $5M MVLS floorNegative equityReverse splitRunway < 6 months

Death-spiral watch Pressure ▼ strength 0.90

Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.

Would confirm: Rising share count in 10-Q cover vs prior quarter; repeated 424B3 resales; another reverse split proposal.
Would invalidate: Notes repaid in cash / equity line terminated (8-K 1.02); share count flat quarter over quarter.
Convertible noteEquity lineMinimum bid deficiencyReverse split

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on GCTK
Alerts
One email the morning GCTK files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for GCTK back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 985 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$1.1Mcash + short-term investments as of Jun 30, 2026
0.9 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$-1.7Mstockholders' equity as of Jun 30, 2026
$5.4Mpublic float (10-K cover)
10.6Mshares outstanding as of Aug 14, 2026 · was 6.3M May 14, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Aug 14, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing 33
Aug 10, 2026 Equity line “equity line” language in 8-K (8-K) filed 2026-08-10 filing 45
Aug 10, 2026 Unregistered sale 8-K Item 3.02 filed 2026-08-10 (accepted 16:05 ET) filing 32
Aug 5, 2026 Equity line “equity line” language in 8-K (EX-10.1) filed 2026-08-05 filing 51
Aug 5, 2026 Convertible note “convertible note” language in 8-K (EX-4.1) filed 2026-08-05 filing 39
Aug 5, 2026 Minimum bid deficiency “min bid” language in 8-K (EX-4.3) filed 2026-08-05 filing 39
Aug 5, 2026 ATM program “atm” language in 8-K (EX-4.2) filed 2026-08-05 filing 38
Aug 5, 2026 PIPE “pipe” language in 8-K (8-K) filed 2026-08-05 filing 33
Aug 5, 2026 Unregistered sale 8-K Item 3.02 filed 2026-08-05 (accepted 17:20 ET) filing 32
Aug 5, 2026 Reverse split “reverse split” language in 8-K (EX-4.1) filed 2026-08-05 filing 32
Aug 5, 2026 New debt obligation 8-K Item 2.03 filed 2026-08-05 (accepted 17:20 ET) filing 27
Jul 29, 2026 Unregistered sale 8-K Item 3.02 filed 2026-07-29 (accepted 17:15 ET) filing 32
Jul 29, 2026 New debt obligation 8-K Item 2.03 filed 2026-07-29 (accepted 17:15 ET) filing 27
Jul 27, 2026 Unregistered sale 8-K Item 3.02 filed 2026-07-27 (accepted 16:30 ET) filing 32
Jul 27, 2026 New debt obligation 8-K Item 2.03 filed 2026-07-27 (accepted 16:30 ET) filing 27
Jul 17, 2026 Reverse split “reverse split” language in DEF 14A (DEF 14A) filed 2026-07-17 filing 27
Jun 30, 2026 Runway < 6 months ~0.9 months runway: liquidity $1,124,000 as of 2026-06-30, burn $15,540,889/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 49
Jun 30, 2026 Share count +25% Shares outstanding 6,259,279 (2026-05-14) -> 10,578,822 (2026-08-14), +69% filing 36
Jun 30, 2026 Negative equity Stockholders' equity $-1,741,000 as of 2026-06-30 filing 31
Jun 30, 2026 Near $5M MVLS floor Public float $5,400,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing 26
Jun 30, 2026 Cash < current liabilities Liquidity $1,124,000 vs current liabilities $2,988,000 filing 21

Other forced raise setups

VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans